GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Aarti Drugs Ltd

Aarti Drugs: MD & CEO Prakash M. Patil to retire Sept 30, 2026

MANAGEMENT ◆ Monitor Closely MEDIUM RISK
📅 Filed on BSE: 31 Jul 2026, 08:10 PM IST  ·  BSE ID: 2f638332-7bd6-4b56-8e27-7ab5120efe2b
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's top leader, who has been with them since the start, is retiring from his executive roles.
🤖 AI Summary
  • MD & CEO Shri Prakash M. Patil to retire September 30, 2026.
  • Resignation is for early retirement to facilitate leadership transition.
  • Shri Patil has served as Chairman since 2014.
  • Board accepted resignation with gratitude; requested continued guidance.
🏢 How This Affects the Company
📈
Business Impact
The departure of a long-standing MD & CEO could influence the company's strategic direction and market positioning.
💰
Financial Impact
No direct financial impact is stated in the filing concerning this management change.
⚙️
Operational Impact
A leadership transition necessitates the appointment of a new MD & CEO, impacting organizational structure and decision-making.
⚠️
Risk Impact
The transition introduces management succession risk, though the request for continued guidance mitigates some uncertainty.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders. Monitor for appointment of new leadership.
👤
Who Is Affected
All shareholders are affected by changes in key leadership, which can influence company strategy and performance.
🔍
Management Signal
The signal is a proactive management succession plan to ensure an orderly transition and continued company stability.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Appointment of new MD & CEO
Announcement of strategic priorities by new leadership
Board composition changes post-retirement
MEDIUM RISK Departure of long-serving MD & CEO introduces leadership succession uncertainty.
💡 Investor Takeaway
Aarti Drugs' Chairman and MD & CEO, Shri Prakash M. Patil, is retiring effective September 30, 2026, after serving the company since inception and as Chairman since 2014.
❓ Frequently Asked Questions
Who is retiring from Aarti Drugs and when?
Shri Prakash M. Patil, Chairman, Managing Director and Chief Executive Officer, is retiring effective close of business hours on September 30, 2026.
Why is Shri Prakash M. Patil retiring?
He expressed a desire to resign on grounds of his intention to get early retirement, believing it is an appropriate time for an orderly leadership transition.
How long has Shri Prakash M. Patil been with Aarti Drugs?
Shri Prakash M. Patil has been associated with the Company since inception and has served as its Chairman since 2014.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.